Y Biologics Inc.
Y-Biologics is Korea’s leading R&D biotech company specializing in antibody drug development with a focus on immuno-oncology. The company has developed innovative platform technologies including Ymax®-ABL, a human antibody library, and ALiCE, a bispecific T-cell engager platform. Its mission is to become a global leader in antibody therapeutics by discovering excellent antibodies and establishing cutting-edge platform technologies. Y-Biologics aims to address unmet medical needs with next-generation immuno-oncology drugs, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates, targeting major immune checkpoints such as PD-1, PD-L1, LAG-3, and VSIG4. The company is actively developing pipelines with promising candidates like YBL-006, YBL-011, YBL-013, and others, with a projected expansion of the market driven by immuno-oncology therapeutics.
Industries
Nr. of Employees
medium (51-250)
Y Biologics Inc.
B715 Daedeok Biz Center, 17 Techno 4-ro, Yuseong-gu, Daejeon 34013 Korea
Patents
Products
PD-1 monoclonal antibody (early clinical candidate)
A fully human monoclonal antibody targeting PD-1 developed as an immune checkpoint inhibitor and progressed into Phase 1 clinical evaluation with associated preclinical and interim clinical data.
PD-L1 × CD3 bispecific T-cell engager (ALiCE format, CMC-stage)
A bispecific T-cell engager that binds PD-L1 on tumor cells and CD3 on T cells using a 2-by-1 bispecific format designed to redirect and activate T cells at tumor sites while limiting systemic activation.
DLK1-targeting antibody–drug conjugate (CMC-stage)
ADC targeting DLK1 that couples an internalizing antibody to a cytotoxic payload to selectively kill DLK1-expressing cancer cells; listed at CMC stage in the pipeline.
B7-H3-targeting antibody–drug conjugate (CMC-stage)
ADC designed to target B7-H3–expressing solid tumors, combining a B7-H3–specific antibody with a cytotoxic payload; listed at CMC stage in the pipeline.
Mono-specific antibodies targeting immune-regulatory proteins (discovery / CMC)
Mono-specific antibody candidates targeting immune-regulatory proteins (examples include LAG-3 and VSIG4) at discovery or CMC stages for potential solid tumor indications.
PD-1 monoclonal antibody (early clinical candidate)
A fully human monoclonal antibody targeting PD-1 developed as an immune checkpoint inhibitor and progressed into Phase 1 clinical evaluation with associated preclinical and interim clinical data.
PD-L1 × CD3 bispecific T-cell engager (ALiCE format, CMC-stage)
A bispecific T-cell engager that binds PD-L1 on tumor cells and CD3 on T cells using a 2-by-1 bispecific format designed to redirect and activate T cells at tumor sites while limiting systemic activation.
DLK1-targeting antibody–drug conjugate (CMC-stage)
ADC targeting DLK1 that couples an internalizing antibody to a cytotoxic payload to selectively kill DLK1-expressing cancer cells; listed at CMC stage in the pipeline.
B7-H3-targeting antibody–drug conjugate (CMC-stage)
ADC designed to target B7-H3–expressing solid tumors, combining a B7-H3–specific antibody with a cytotoxic payload; listed at CMC stage in the pipeline.
Mono-specific antibodies targeting immune-regulatory proteins (discovery / CMC)
Mono-specific antibody candidates targeting immune-regulatory proteins (examples include LAG-3 and VSIG4) at discovery or CMC stages for potential solid tumor indications.
Services
Collaborative research, co-development programs and licensing agreements with external pharmaceutical and biotech partners.
Reference to third-party contract research organization services for preclinical and development activities.
On-site process development and CMC support for biologics and ADC candidates provided from a dedicated CMC facility.
Collaborative research, co-development programs and licensing agreements with external pharmaceutical and biotech partners.
Reference to third-party contract research organization services for preclinical and development activities.
On-site process development and CMC support for biologics and ADC candidates provided from a dedicated CMC facility.
Expertise Areas
- Antibody discovery and engineering
- Bispecific T-cell engager platform engineering
- Antibody–drug conjugate development
- Immuno-oncology therapeutic development
Key Technologies
- Phage-display scFv libraries
- Single-domain antibody (nanobody) libraries
- 2-by-1 bispecific antibody format (bivalent tumor / monovalent CD3)
- Antibody–drug conjugation and linker chemistry
News & Updates
Meritz Securities reports on Y-Biologics' development of immune-boosting immunocytokines based on antibody libraries, including PD-1xVEGF bispecific antibodies with IL-2.
Y-Biologics announced its research results on pH-responsive antibody-based next-generation ADC at AACR 2025, demonstrating improved stability and tumor targeting.
Y-Biologics registered a patent for its bispecific T cell engager platform, ALiCE, in the US.
Meritz Securities reports on Y-Biologics' development of immune-boosting immunocytokines based on antibody libraries, including PD-1xVEGF bispecific antibodies with IL-2.
Y-Biologics announced its research results on pH-responsive antibody-based next-generation ADC at AACR 2025, demonstrating improved stability and tumor targeting.
Y-Biologics registered a patent for its bispecific T cell engager platform, ALiCE, in the US.